Low titers of measles antibody in mothers whose infants suffered from measles before eligible age for measles vaccination

Virology Journal

Volumn 7, Issue , 2010, Pages

  Zhao, Hong ^a   Lu, Pei Shan ^b   Hu, Yali ^c   Wu, Qiaozhen ^c   Yao, Wenhu ^a   Zhou, Yi Hua ^c  

^a Nanjing Second Hospital   (China)

^b JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEASLES ANTIBODY; MEASLES VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; FEMALE; HUMAN; IMMUNITY; INFANT; INFANT DISEASE; MALE; MEASLES; MEASLES VACCINATION; MOTHER; ADULT; BLOOD; IMMUNOLOGY; PASSIVE IMMUNIZATION;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHINA; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; MALE; MEASLES; MEASLES VACCINE; MOTHERS;

EID: 77951859432     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-87     Document Type: Article

References (21)

1. Progress in accelerated measles control in the People's Republic of China, 1991-2000. Lixia W, Guang Z, Lee LA, Zhiwei Y, Jingjin Y, Jun Z, Xiaofeng L, Chang X, Huqun B, J Infect Dis 2003 187 252 257 10.1086/368045 12721922 (Pubitemid 36583963)
2. Analysis on epidemiological characteristics of age distribution of measles in China during 2003-2006. Li L, Yu WZ, Shui TJ, Ma C, Wen N, Liang XF, Chin J Vac Immunol 2007 13 101 105 (in Chinese)
3. Fighting against measles: the history and present status in China. Wu T, Chin J Epidemiol 2000 21 143 146 (in Chinese)
4. Clinical epidemiological characteristics of children with measles in Shanghai from January to June in 2005. Yang ZH, Wang XH, Zhu QR, Chin J Infect Dis 2007 25 25 28 (in Chinese)
5. Analysis of the cause of increased measles incidence in Xinjiang, China in 2004. Yu X, Wang S, Guan J, Mahemuti, Purhati, Gou A, Liu Q, Jin X, Ghildyal R, Pediatr Infect Dis J 2007 26 513 518 10.1097/INF.0b013e31805ce299 17529869 (Pubitemid 46847313)
6. Investigation on immunity of measles in children in counties with different 4 vaccine coverage rates: National Immunization Program Review in 2004. Wang H, Mao N, Xu W, Zhou Y, Guo X, Cao L, Chin J Vac Immunol 2007 13 79 83 (in Chinese)
7. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Leuridan E, Van Damme P, Vaccine 2007 25 6296 6304 10.1016/j.vaccine.2007.06.020 17629601 (Pubitemid 47090234)
8. Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection. Erdman DD, Heath JL, Watson JC, Markowitz LE, Bellini WJ, J Med Virol 1993 41 44 48 10.1002/jmv.1890410110 8228936 (Pubitemid 23267502)
9. Immunoglobulin M antibody response to measles virus following natural virus infection, primary vaccination, and reexposure to the virus. Nates S, Rey G, Giordano M, Medeot S, Depetris A, Boshell J, de Wolff CD, Viral Immunol 1997 10 165 173 10.1089/vim.1997.10.165 9344339 (Pubitemid 27478673)
10. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. Helfand RF, Kebede S, Gary HE Jr, Beyene H, Bellini WJ, Clin Diagn Lab Immunol 1999 6 178 180 10066650 (Pubitemid 29124961)
11. Immunologic studies of measles. Stokes J Jr, Reilly CM, Buynak EB, Hilleman MR, Am J Hyg 1961 74 293 303 13917381
12. Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine. Arguelles MH, Orellana ML, Castello AA, Villegas GA, Masini M, Belizan AL, Gonzalez Ayala S, Vera OD, Glikmann G, J Clin Microbiol 2006 44 2733 2738 10.1128/JCM.00980-05 16891485 (Pubitemid 44228564)
13. Comparison of the neutralizing and ELISA antibody titers to measles virus in human sera and in gamma globulin preparations. Rabenau HF, Marianov B, Wicker S, Allwinn R, Med Microbiol Immunol 2007 196 151 155 10.1007/s00430-007- 0037-2 17308917 (Pubitemid 47300251)
14. Measles vaccine. Strebel PM, Papania MJ, Halsey NA, Vaccine Philadelphia: Saunders, Plotkin SA, Orenstein WA, 4 2004 389 440
15. Increased susceptibility to measles in infants in the United States. Papania MJ, Baughman AL, Lee S, Cheek JE, Atkinson W, Redd SC, Spitalny K, Finelli L, Markowitz L, Pediatrics 1999 104 59 10.1542/peds.104.5.e59 10545585
16. Progress in Italy in control and elimination of measles and congenital rubella. Bonanni P, Bechini A, Boccalini S, Peruzzi M, Tiscione E, Boncompagni G, Mannelli F, Salmaso S, Filia A, Ciofi degli Atti M, Vaccine 2007 25 3105 3110 10.1016/j.vaccine.2007.01.019 17306425 (Pubitemid 46482741)
17. The impact of Australia's measles control programme over the past decade. Gidding HF, Epidemiol Infect 2005 133 99 105 10.1017/S0950268804003073 15724716 (Pubitemid 40276979)
18. Epidemiology characteristics of measles in the status of high coverage of MV and discussion on the necessity of immunization strategy adjustment. Cheng Z, Ni J, Wang S, Chin J Dis Control Prev 2007 11 10 14 (in Chinese)
19. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. Martins CL, Garly ML, Bale C, Rodrigues A, Ravn H, Whittle HC, Lisse IM, Aaby P, BMJ 2008 337 661 10.1136/bmj.a661 18653640
20. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y, JAMA 1998 280 527 532 10.1001/jama.280.6.527 9707142 (Pubitemid 28377671)
21. Neutralization of measles virus infectivity and antibody-dependent cell-mediated cytotoxicity activity against an Epstein-Barr virus-infected cell line by intravenous immunoglobulin G. Colomar M, Puga I, Lopez M, Massot M, Jorquera JI, Reina M, Vilaro S, Espel E, Clin Diagn Lab Immunol 2003 10 751 756 12965899 (Pubitemid 37129482)